Co-Founder and Chief Executive Officer
Reuben holds 18 years of commercial biopharmaceutical industry experience.
Prior to co-founding Link Biologics, Reuben worked for Novo Nordisk in various leadership roles including Business Unit Head, Global Life Cycle Management Lead for a >$1bn product portfolio, and Global Product Director for multiple early-stage assets targeting billion-dollar markets.
.
Reuben holds an MSc in Drug Design from University College London (UCL).
Co-Founder & Chief Scientific Officer
Tony is a Professor of Biochemistry within the Manchester Cell-Matrix Centre (University of Manchester), where he is Lead for Translation.
Tony was elected to the Academy of Medical Sciences in 2025, the Academy of Europe in 2012 and was formerly a member of the Council of the International Society for Matrix Biology (2016-2019) and President of the International Society for Hyaluronan Sciences (2021-2023).
Tony holds a DPhil in Biochemistry from the University of Oxford and has worked on TSG-6 for >30 years.
Co-Founder & Scientific Director
Caroline is a Senior Lecturer in Immune Response
& Disease at the University of Manchester, where she is also the Lead for Postgraduate Research within the Division of Cell Matrix Biology and
Regenerative Medicine.
Caroline holds a DPhil in Biochemistry from the University of Oxford and has expertise in protein expression, molecular and cellular biology, and in vivo models. She has worked on TSG-6 for >20 years, co-leading multiple basic research and translational programmes and securing
significant funding.
Associate Scientific Director
Nikos is a biochemist with over 15 years of experience in protein engineering, inflammation, and translational biology research.
Prior to joining Link Biologics, Nikos held postdoctoral positions at the Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, and the Hellenic Pasteur Institute, where he led projects on therapeutic proteins for inflammatory diseases.
Nikos holds a PhD in Biochemistry from the University of Nottingham.
Programme and Non-Clinical Director
Lorna holds over 20 years of biopharmaceutical R&D experience across academic and industry sectors.
Prior to joining Link Biologics, Lorna served as R&D Director at Cambrian Bio, Associate Director of Research at Oxstem, and Principal Scientist & Programme Manager at e-therapeutics, where she led multidisciplinary teams from early discovery through to clinical strategy.
Lorna holds a PhD in Cell Biology from Cardiff University.
Senior Clinical Lead
Majid is an ophthalmologist by training with over 25 years of experience in ophthalmology drug development and medical affairs.
Before joining Link Biologics, Majid served as VP of Clinical Development at OcuTerra Therapeutics, where he led an early-stage programme for diabetic retinopathy. Throughout his career, he has held senior clinical leadership positions, including Global Clinical Lead at Bayer and Allergan, Program Lead at Novartis, and senior roles at Roche, where he directed the development of therapies across both front- and back-of-the-eye indications.
Operations Assistant
Sophie contributes to the operational and scientific activities at Link Biologics. She combines scientific knowledge with organisational expertise, drawing on her education and experience in private healthcare operations.
She holds a BSc in Biological Sciences and an MSc in Genomic Medicine from King’s College London.
Co-Founder and
Chief Executive Officer
Reuben holds 18 years of commercial biopharmaceutical industry experience.
Prior to co-founding Link Biologics, Reuben worked for Novo Nordisk in various leadership roles including Business Unit Head, Global Life Cycle Management Lead for a >$1bn product portfolio, and Global Product Director for multiple early-stage assets targeting billion-dollar markets.
Reuben holds an MSc in Drug Design from University College London (UCL).
Co-Founder and
Chief Scientific Officer
Tony is a Professor of Biochemistry within the Manchester Cell-Matrix Centre (University of Manchester), where he is Lead for Translation.
Tony was elected to the Academy of Medical Sciences in 2025, the Academy of Europe in 2012 and was formerly a member of the Council of the International Society for Matrix Biology (2016-2019) and President of the International Society for Hyaluronan Sciences (2021-2023).
Tony holds a DPhil in Biochemistry from the University of Oxford and has worked on TSG-6 for >30 years.
Co-Founder and
Scientific Director
Caroline is a Senior Lecturer in Immune Response & Disease at the University of Manchester, where she is also the Lead for Postgraduate Research within the Division of Cell Matrix Biology and Regenerative Medicine.
Caroline holds a DPhil in Biochemistry from the University of Oxford and has expertise in protein expression, molecular and cellular biology, and in vivo models. She has worked on TSG-6 for >20 years, co-leading multiple basic research and translational programmes and securing significant funding.
Associate
Scientific Director
Nikos is a biochemist with over 15 years of experience in protein engineering, inflammation, and translational biology research.
Prior to joining Link Biologics, Nikos held postdoctoral positions at the Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, and the Hellenic Pasteur Institute, where he led projects on therapeutic proteins for inflammatory diseases.
Nikos holds a PhD in Biochemistry from the University of Nottingham.
Programme and Non-Clinical Director
Lorna holds over 20 years of biopharmaceutical R&D experience across academic and industry sectors.
Prior to joining Link Biologics, Lorna served as R&D Director at Cambrian Bio, Associate Director of Research at Oxstem, and Principal Scientist & Programme Manager at e-therapeutics, where she led multidisciplinary teams from early discovery through to clinical strategy.
Lorna holds a PhD in Cell Biology from Cardiff University.
Senior Clinical Lead
Majid is an ophthalmologist by training with over 25 years of experience in ophthalmology drug development and medical affairs.
Before joining Link Biologics, Majid served as VP of Clinical Development at OcuTerra Therapeutics, where he led an early-stage programme for diabetic retinopathy. Throughout his career, he has held senior clinical leadership positions, including Global Clinical Lead at Bayer and Allergan, Program Lead at Novartis, and senior roles at Roche, where he directed the development of therapies across both front- and back-of-the-eye indications.
Operations Assistant
Sophie contributes to the operational and scientific activities at Link Biologics. She combines scientific knowledge with organisational expertise, drawing on her educationand experience in private healthcare operations.
She holds a BSc in Biological Sciences and an MSc in Genomic Medicine from King’s College London.
124 City Road, London, EC1V 2NX, U.K.
Registered in England and Wales. Registration no. 12550888